A double board-certified physician specializing in obesity medicine and family medicine, Kristin Baier, MD, worked for a private practice in southern California prior to joining Calibrate as a full-time physician
The most common side effects are gastrointestinal, including nausea (occurring in 20-30% of patients), diarrhea, vomiting, constipation, and abdominal discomfort
Prolonged nightly fasting and breast cancer prognosis
Oral GLP-1 formulations are adding manufacturing complexity in a different dimension: on December 22, 2025, the FDA approved Novo Nordisk's oral Wegovy 25 mg as the first oral GLP-1 therapy for weight loss, bringing with it the manufacturing requirements of oral solid dosage pharmaceutical production at commercial scale, a fundamentally different infrastructure challenge from parenteral peptide API synthesis
By the time an oral Sermorelin product passes through the stomach, very little of the intact peptide remains, and what does survive is unlikely to reach the pituitary in any meaningful concentration